Drugs

As the complexities of modern living escalate, there is a growing emphasis on comprehensive health and wellness as a means to sustain a high quality of life. In line with this endeavor, Amway India, a pioneer in health and wellness […]

In a landmark achievement within the global Ayurveda community, over 70 learners from upwards of 30 nations united to embark on an innovative 3-year Ayurveda, Siddha Veda education program. This significant milestone, orchestrated by the Ayushakti Academy of Ayurveda, was

Eisai Co., Ltd. and Biogen Inc. have made an announcement regarding the approval from Mexico’s Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) for their humanized anti-soluble aggregated amyloid-beta (Aß) monoclonal antibody, “Leqembi” (lecanemab), designed for early Alzheimer’s disease

**Merus N.V., a company specializing in oncology and working on groundbreaking, comprehensive, multispecific antibodies (Biclonics and Triclonics), announced the FDA’s nod for Bizengri (zenocutuzumab-zbco).** This milestone marks the first approved therapy for adults with advanced unresectable or metastatic pancreatic adenocarcinoma

GSK plc, in collaboration with Medicines for Malaria Venture (MMV), has revealed that the World Health Organization (WHO) has granted prequalification status to tafenoquine, marking it as the first single-dose treatment aimed at preventing relapses of *Plasmodium vivax* (P. vivax)

AstraZeneca has announced that Iskra Reic will now serve as the executive vice president (EVP) for international divisions, overseeing the strategic direction and fostering sustainable development throughout regions including China, Asian and Eurasian markets, Middle East & Africa, Latin America,

Eli Lilly and Company revealed the primary results of the SURMOUNT-5 Phase 3b open-label randomized clinical trial. In this study, Zepbound (tirzepatide) achieved a 47% greater relative weight loss than Wegovy (semaglutide). On average, participants using Zepbound experienced a 20.2%

The World Health Organization has endorsed the prequalification of the Xpert MTB/RIF Ultra, a molecular diagnostic test for tuberculosis. This marks the first TB test approved for both disease diagnosis and antibiotic susceptibility testing, adhering to WHO’s rigorous prequalification criteria.

Roche has announced that their supplemental Biologics License Application (sBLA) for Columvi (glofitamab), when used in combination with gemcitabine and oxaliplatin (GemOx), has been accepted by the US Food and Drug Administration (FDA). This combination is intended for patients suffering

GSK plc has disclosed a new agreement with Chongqing Zhifei Biological Products, Ltd. (Zhifei) to modify the existing arrangement for Zhifei’s commercialisation of GSK’s Shingrix shingles vaccine within mainland China. This amended pact lengthens the initial 3-year timespan (2024-2026) granting